ALUNBRIG® (brigatinib) Expert Opinion Video Series: Appropriate sequencing of ALK TKI therapies in ALK+ aNSCLC in England
Prescribing information is available at the top of the page.
Listen to Prof Samreen Ahmed explore the funded ALK TKI treatment options available for ALK+ aNSCLC in England as per NICE TA, CDF and NHS England Blueteq eligibility criteria.
Prof Ahmed overviews the funded first- and second-line ALK TKI options in England in ALK+ aNSCLC and discusses where ALUNBRIG is placed in the treatment algorithm as a NICE recommended monotherapy for the treatment of adult patients with ALK+ aNSCLC, previously not treated with an ALK inhibitor, or previously treated with crizotinib.
Prof Ahmed also highlights lorlatinib as a funded treatment option post first-line ALUNBRIG, as per Blueteq eligibility criteria.
ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; aNSCLC, advanced non-small cell lung cancer; CDF, Cancer Drug Fund; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; TA, technology appraisals; TKI, tyrosine kinase inhibitor.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
